Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of “Buy” from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given a consensus recommendation of “Buy” by the eleven analysts that are currently covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $57.10.

A number of equities research analysts have recently commented on the company. Leerink Partners increased their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Citigroup lifted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th.

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 2,500 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $47.10, for a total value of $117,750.00. Following the sale, the senior vice president now owns 2,426 shares of the company’s stock, valued at $114,264.60. This trade represents a 50.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the sale, the chief executive officer now owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. This trade represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,737 shares of company stock worth $556,098 in the last three months. Corporate insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently modified their holdings of MIRM. Quest Partners LLC increased its holdings in shares of Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after acquiring an additional 1,127 shares during the last quarter. Amalgamated Bank lifted its position in Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after acquiring an additional 318 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $189,000. Finally, ProShare Advisors LLC acquired a new position in Mirum Pharmaceuticals during the second quarter worth $213,000.

Mirum Pharmaceuticals Trading Up 6.9 %

NASDAQ:MIRM opened at $46.33 on Thursday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a market capitalization of $2.22 billion, a PE ratio of -22.94 and a beta of 0.98. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $48.89. The firm’s 50 day moving average is $43.07 and its 200 day moving average is $40.91.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. During the same quarter in the prior year, the firm earned ($0.57) earnings per share. The firm’s revenue was up 89.4% on a year-over-year basis. Sell-side analysts expect that Mirum Pharmaceuticals will post -1.46 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.